Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 2b study, 834 adults with BMI ≥25 kg/m2 and type 2 diabetes inadequately controlled with metformin (glycated hemoglobin A1c [HbA1c] of 7.0%–10.5% [53–91 mmol/mol]) were randomized to double-blind cotadutide 100 μg (n = 100), 200 μg (n = 256), or 300 μg (n = 256); placebo (n = 110); or open-label liraglutide 1.8 mg (n = 110)—all administered subcutaneously. Coprimary end points were changes in HbA1c and body weight at week 14. The originally randomized interventions were continued to week 54. Liver damage biomarkers and liver fibrosis algorithms were assessed. RESULTS: Cotadutide significantly decreased HbA1c and body weight at weeks 14 and 54 versus placebo (all P < 0.001). Improvements in lipid profile, AST and ALT levels, propeptide of type III collagen level, fibrosis-4 index, and nonalcoholic fatty liver disease fibrosis score were observed with cotadutide 300 μg versus placebo, but not with liraglutide. Weight loss with cotadutide 200 μg was similar to that with liraglutide 1.8 mg and greater with cotadutide 300 μg versus liraglutide 1.8 mg. The most common adverse events with cotadutide (nausea, 35%; vomiting, 17%) decreased over time. CONCLUSIONS: Cotadutide treatment for 54 weeks improved glycemic control and weight loss in participants with overweight/obesity and type 2 diabetes. Ad hoc analyses demonstrated improvements in hepatic parameters and support further evaluation of cotadutide in NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cotadutide, but not liraglutide improved hepatic parameters and metabolic dysfunction-associated steatohepatitis (MASH) with similar weight loss with 200 μg cotadutide compared to 1.8 mg liraglutide and greater with 300 μg cotadutide versus 1.8 mg liraglutide [47].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“cotadutide did induce a dose-dependent 4–8 times greater reduction in triglycerides over liraglutide.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first GLP-1R/GCGR agonist to be put in clinical trials, cotadutide, produced comparable reductions in body weight and blood sugar levels in adults with overweight or obesity, and T2D as 1.8 mg of liraglutide [82].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Through a phase 2b trial, cotadutide 300 μg was shown to significantly improve liver injury enzymes, propeptide of type III collagen level, FIB-4, and NAFLD fibrosis score compared to placebo (but not compared to liraglutide) and reduce body weight more than treatment with liraglutide 1.8 mg.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [173]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from combining existing drugs, the development of dual GLP-1/glucagon receptor or GLP-1/GIP agonists or even triagonists237 with first promising results in NASH237–239 may show up another promising approach in drug development.”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [239]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“The pathology of NAFLD can progress further to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and end-stage cirrhosis (7).”
BackgroundByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042 · cited 1×
“Because the majority of deaths linked with NAFLD are attributable to cardiovascular disease, and given the close association between type 2 diabetes and NAFLD, therapeutic agents that improve both liver health and cardiometabolic risk are clinically valuable (36,37).”
BackgroundFox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C.-Y., Vasan, R. S., Murabito, J. M., Meigs, J. B., Cupples, L. A., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.675355 · Cited by 2,882 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · cited 1×
“In previous studies of participants with obesity and NASH, weight loss achieved through lifestyle modifications decreased intrahepatic fat and ALT levels while improving hepatic fibrosis (32,33).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has been shown to improve glycemic control (13), delay gastric emptying, and induce weight loss in people with type 2 diabetes (14,15).”
BackgroundDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Cited by
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“147 Triple agonist: Triple agonists go even further.”
BackgroundAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
The Role of Obesity in Type 2 Diabetes Mellitus—An Overview
Chandrasekaran, P., & Weiskirchen, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031882 · Cited by 465
“It does this by selectively stimulating the activation of beige adipocytes in white adipose tissue (WAT) to promote “WAT browning” and by regulating the composition of intestinal microbial products, such as acetate and lactate which are known inducers of WAT browning [127].”
BackgroundRosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
“Some results of clinical studies have been published and promise effect sizes not usually observed with selective GLP-1 RAs alone [93, 94].”
BackgroundXu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Current treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“[173] evaluated the effects of cotadutide, a dual GLP-1 and glucagon receptor agonist, in 834 overweight/obesity and uncontrolled T2DM patients.”
BackgroundIncretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
Self-citationNovel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202
Bossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175
Boutari, C., DeMarsilis, A., & Mantzoros, C. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110773 · Cited by 161
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 197
Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R., & Hennige, A. M. (2024) · Diabetologia · doi:10.1007/s00125-023-06053-9 · Cited by 138
“[6].”
BackgroundBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Non‐alcoholic fatty liver disease and type 2 diabetes: An update
Lee, C., Lui, D. T. W., & Lam, K. S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13756 · Cited by 159
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Habibullah, M., Jemmieh, K., Ouda, A., Haider, M. Z., Malki, M. I., & Elzouki, A.-N. Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1291501 · Cited by 137
An update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111
The past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Ji, L., Jiang, H., Bi, Y., Li, H., Tian, J., Liu, D., Zhao, Y., Qiu, W., Huang, C., Chen, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2411528 · Cited by 125
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“Notably, there were improvements in biomarkers of MASH with cotadutide treatment that were not seen with the comparator treatment (liraglutide at 1.8 mg) 118 .”
InfluentialAssessing the Risk of Bias in Randomized Clinical Trials With Large Language Models
Lai, H., Ge, L., Sun, M., Pan, B., Huang, J., Hou, L., Yang, Q., Liu, J., Liu, J., Ye, Z., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.12687 · Cited by 103
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 136
Abushamat, L. A., Shah, P. A., Eckel, R. H., Harrison, S. A., & Barb, D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.01.032 · Cited by 92
Zhang, B., Cheng, Z., Chen, J., Zhang, X., Liu, D., Jiang, H., Ma, G., Wang, X., Gan, S., Sun, J., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1287 · Cited by 91
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
“Gastrointestinal side effects observed under cotadutide effects are similar in quality but more severe than those under GLP-1RA treatment (52).”
BackgroundStriking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
Parker, V. E. R., Hoang, T., Schlichthaar, H., Gibb, F. W., Wenzel, B., Posch, M. G., Rose, L., Chang, Y., Petrone, M., Hansen, L., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14712 · Cited by 80
“Beneficial liver-specific effects of cotadutide have been attributed to glucagon receptor signaling.(22,23) Cotadutide has been shown to promote a reduction in liver glycogen after short-term treatment, providing suggestive evidence of target engagement of the glucagon receptor in the liver.”
BackgroundSelf-citationThe molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
“11% at 200 μg, relative to liraglutide), although these changes were not significant [126].”
Diabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
Newsome, P. N., & Loomba, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186425 · Cited by 90
“Together, dual agonists including cotadutide have shown significantly greater liver fat reductions than GLP-1 analogs alone, providing a theoretical rationale of higher potency on both MASH resolution and potentially fibrosis improvements (21).”
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 76
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
“114,115 Moreover, triple agonists, for example, GLP-1/GIP/glucagon agonists are being explored as potential treatments, although data from clinical trials are limited and in early stage.”
BackgroundGLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease
Wit, M., Viera, J. T., Strohmeyer, A., Klingenspor, M., Hankir, M. K., & Sumara, G. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114742 · Cited by 73
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01566-x · Cited by 61
“The first GLP-1R/GCGR agonist to be put in clinical trials, cotadutide, produced comparable reductions in body weight and blood sugar levels in adults with overweight or obesity, and T2D as 1.8 mg of liraglutide [82].”
MethodInfluentialObesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Artasensi, A., Mazzolari, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2023) · Molecules · doi:10.3390/molecules28073094 · Cited by 74
“2% with a dose of 300 mg cotadutide [67].”
BackgroundInfluentialShankar, S. S., Daniels, S. J., Robertson, D., Sarv, J., Sánchez, J., Carter, D., Jermutus, L., Challis, B., & Sanyal, A. J. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.04.017 · Cited by 56
Self-citationDiabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
Parker, V. E. R., Robertson, D., Erazo-Tapia, E., Havekes, B., Phielix, E., de Ligt, M., Roumans, K. H. M., Mevenkamp, J., Sjoberg, F., Schrauwen-Hinderling, V. B., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00938-0 · Cited by 53
Self-citationPharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Александровна, П. В., Bezborodkina, N. N., & Okovityi, S. V. (2022) · Biomedicines · doi:10.3390/biomedicines10020274 · Cited by 58
MASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
MASH clinical trials and drugs pipeline: An impending tsunami
Noureddin, M. (2025) · Hepatology · doi:10.1097/hep.0000000000000860 · Cited by 48
Targher, G., Mantovani, A., Byrne, C. D., & Tilg, H. (2025) · Gut · doi:10.1136/gutjnl-2024-334023 · Cited by 48
“42 43 In a phase 2a placebo-controlled RCT, Shankar et al examined the efficacy and safety of once-daily subcutaneous injections of cotadutide (600 µ g or 300 µ g) or placebo in 74 obese participants with biopsy-proven MASH and liver fibrosis.”
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
“…(MEDI0382) is the most extensively developed dual GLP-1/ glucagon receptor agonist, showing signi fi cant improvements in glucose control,BW(likelymediatedbyreducedenergyintakeratherthanincreased energyexpenditure),hepaticfat,andalbuminuriainasmallRCTon patientswithT2Dandoverweightorobesity 45,46 .”
Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48
Winther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
Melson, E., Miras, A. D., & Papamargaritis, D. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0144 · Cited by 46
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Friedrichsen, M. H., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101801 · Cited by 46
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Pοlyzos, S. A., Goulis, D. G., Γιουλεμέ, Ό., Germanidis, G. S., & Goulas, A. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00474-0 · Cited by 46
“hepatic fibrosis, findings rendering cotadutide a candidate for the treatment of NASH [87].”
BackgroundZhang, Y., Chen, G., Wang, W., Yang, D., Zhu, D., & Jing, Y. (2024) · Bone · doi:10.1016/j.bone.2024.117338 · Cited by 52
Qassab, M. A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J. K., Katrib, N., Chaarani, N., Attieh, P., Kanaan, A., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040285 · Cited by 64
Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
“Cotadutide, but not liraglutide improved hepatic parameters and metabolic dysfunction-associated steatohepatitis (MASH) with similar weight loss with 200 μg cotadutide compared to 1.8 mg liraglutide and greater with 300 μg cotadutide versus 1.8 mg liraglutide [47].”
BackgroundInfluentialPharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 67
Glucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“A multicenter study evaluated the effects of subcutaneously administered cotadutide in 834 participants in daily doses of 100 µ g, 200 µ g, and 300 µ g compared with placebo and 1.8 mg liraglutide daily [101].”
BackgroundInfluentialObesity pharmacotherapy: incretin action in the central nervous system
Boer, G. A., Hay, D. L., & Tups, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.11.001 · Cited by 51
Metabolic Messengers: glucagon
MacDonald, P. E., & Rorsman, P. (2023) · Nature Metabolism · doi:10.1038/s42255-022-00725-3 · Cited by 43
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Domingues, I., Leclercq, I. A., & Beloqui, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.040 · Cited by 45
Peptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43
“treatment (completion rates: 73–77 % for Cotadutide, 81 % for placebo, 94 % for liraglutide) [232].”
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Cotadutide (MEDI0382) / SC, qd T2DM NASH CKD Obesity Phase 2 Phase 2 Phase 2 Phase 1 [94] [95] [96] [97] Efinopegdutide (MK-6024) / SC, qw NASH Phase 2 /”
BackgroundStructural analysis of the dual agonism at GLP-1R and GCGR
Li, Y., Zhou, Q., Dai, A., Zhao, F., Chang, R., Ying, T., Wu, B., Yang, D., Wang, M., & Cong, Z. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303696120 · Cited by 49
“In a phase 2b clinical study, improvements across metabolic and hepatic parameters in participants with NASH were more pronounced than liraglutide, and the reduction in liver glycogen after short-term treatment also provided suggestive evidence of target engagement of GCGR (43).”
Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 48
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“Cotadutide 300 ug improves lipid profile, AST and ALT and fibrosis-4 index, but not more than liraglutide [103].”
Incretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 40
Karakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 56
Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte
Habegger, K. M. (2022) · Diabetes · doi:10.2337/dbi22-0002 · Cited by 44
Movahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 46
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
Wang, Z., Ye, M., Zhang, X., Zhang, P., Cai, J., Li, H., & She, Z. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.010 · Cited by 40
Glucagon in type 2 diabetes: Friend or foe?
Caruso, I., Marrano, N., Biondi, G., Genchi, V. A., D'Oria, R., Sorice, G. P., Perrini, S., Cignarelli, A., Natalicchio, A., Laviola, L., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3609 · Cited by 35
“8 mg at 54 weeks.(143,148) In the same study, liraglutide 1.”
BackgroundResultMolecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Filipović, B. F., Marjanovic-Haljilji, M., Mijac, D. D., Lukić, S., Kapor, S., Kapor, S., Starčević, A., Popovic, D. D., & Djoković, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110573 · Cited by 37
“Modified GLP1 and GIP peptides such as cotadutide, tirzepatide, and efinopegdutide are in early clinical trials and results will be published soon [89,90].”
Glucagon receptor signaling at white adipose tissue does not regulate lipolysis
Vasileva, A., Marx, T. R., Beaudry, J. L., & Stern, J. H. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00078.2022 · Cited by 36
GLP‐1 analogs and regional adiposity: A systematic review and meta‐analysis
Akoumianakis, I., Zagaliotis, A., Konstantaraki, M., & Filippatos, T. D. (2023) · Obesity Reviews · doi:10.1111/obr.13574 · Cited by 37
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
“8 mg.(58) A dose-dependent delay in gastric emptying time was observed with cotadutide over time, with a lesser but discernable difference versus placebo at day 50 and at followup.”
BackgroundCurrent challenges and future perspectives in treating patients with NAFLD-related cirrhosis
Mallet, M., Silaghi, C. A., Sultanik, P., Conti, F., Rudler, M., Ratziu, V., Thabut, D., & Pais, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000456 · Cited by 34
“[69] Dual agonists [glucagon-like peptide-1 receptor agonists ((GLP1)/ gastric inhibitory peptides or GLP1-glucagon)] are now being tested in patients with T2DM, and preliminary results also support their usefulness in NAFLD, [70,71] but no safety or efficacy data are available in cirrhosis.”
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
“256 The GCGR/GLP-1R agonist, BI 456906 257 and cotadutide (MEDI0382), entered phase II trials, 258 with the latter being recently terminated for further development.”
BackgroundPuengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
“…cotadutide has previously shown significant impact on dysregulated hepatic glycogen synthesis, hepatic fat content, and noninvasive fibrosis scores (NCT03550378; NCT03235050) – beneficial effects that have been confirmed independently in obese subjects with MASLD and MASH (NCT04019561) [59,60].”
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 36
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 37
“Subcutaneous, 1/day 300 μg daily ↓ Liver fat content ↓ Serum ALT, AST, GGT ↓↓ Serum cholesterol, TG ↓ Pro-C3 ↓ FIB-4, NFS NCT03235050 NCT04019561 NCT05364931 NCT05294458 NCT05668936 [131]”
BackgroundObesity Management in the Primary Prevention of Hepatocellular Carcinoma
Zunica, E. R. M., Heintz, E. C., Axelrod, C. L., & Kirwan, J. P. (2022) · Cancers · doi:10.3390/cancers14164051 · Cited by 32
360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 37
Metadata
- Authors
- Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P.
- Affiliations
- AstraZeneca (United States) (US)
- Pennington Biomedical Research Center (US)
- AstraZeneca (Sweden) (SE)
- 5Division of Endocrinology, University Hospital Leipzig, Leipzig, Germany
- AstraZeneca (United Kingdom) (GB)
- 4Clinical Metabolism, Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- Corresponding author
- Nahra, Rajaa
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-06-01
- Volume
- 44
- Issue
- 6
- Pages
- 1433-1442
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC8247525
- OpenAlex
- W3160773731
- Semantic Scholar
- 0019fb9a1c6044e014f9a7ae0dd18ea9907668eb
- Cited by
- 323
- References
- 47
- Citations by year
- 2026: 36 · 2025: 65 · 2024: 76 · 2023: 83 · 2022: 48 · 2021: 14
- FWCI
- 41.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-10-13)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, glucagon receptor agonist, type 2 diabetes, obesity, overweight, glycemic control, HbA1c, weight loss, non-alcoholic fatty liver disease, liver fibrosis, liver injury biomarkers, liraglutide, lipid profile, adverse events, nausea and vomiting, dose comparison
- MeSH terms
- Liraglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Liver, Obesity, Peptides, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.